W
William Sperduto
Researcher at Duke University
Publications - 15
Citations - 1249
William Sperduto is an academic researcher from Duke University. The author has contributed to research in topics: Lung cancer & Hazard ratio. The author has an hindex of 10, co-authored 13 publications receiving 753 citations. Previous affiliations of William Sperduto include University of Minnesota.
Papers
More filters
Journal ArticleDOI
Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA)
Paul W. Sperduto,T. Jonathan Yang,Kathryn Beal,Hubert Y. Pan,Paul D. Brown,Ananta S Bangdiwala,Ryan Shanley,Norman Yeh,Laurie E. Gaspar,Steve Braunstein,Penny K. Sneed,John M Boyle,John P. Kirkpatrick,Kimberley S. Mak,Helen A. Shih,Alex Engelman,David Roberge,Nils D. Arvold,Brian M. Alexander,Mark M. Awad,Joseph N. Contessa,Veronica Chiang,J.G. Hardie,Daniel J. Ma,Emil Lou,William Sperduto,Minesh P. Mehta +26 more
TL;DR: The updated Lung-molGPA incorporating gene alteration data into the DS-GPA is a user-friendly tool that may facilitate clinical decision making and appropriate stratification of future clinical trials.
Journal ArticleDOI
Survival in Patients with Brain Metastases: Summary Report on the Updated Diagnosis-Specific Graded Prognostic Assessment and Definition of the Eligibility Quotient
Paul W. Sperduto,Shane Mesko,Jing Li,Daniel N. Cagney,Ayal A. Aizer,Nan Lin,Eric Nesbit,Tim J. Kruser,Jason Chan,Steve Braunstein,Jessica W. Lee,John P. Kirkpatrick,William G. Breen,Paul D. Brown,Diana D. Shi,Helen A. Shih,Hany Soliman,Arjun Sahgal,Ryan Shanley,William Sperduto,Emil Lou,Ashlyn S. Everett,Drexell Hunter Boggs,Laura Masucci,David Roberge,Jill Remick,Kristin A. Plichta,John M. Buatti,Supriya K. Jain,Laurie E. Gaspar,Cheng-Chia Wu,Tony J. C. Wang,John Bryant,Michael D. Chuong,Yi An,Veronica Chiang,Toshimichi Nakano,Hidefumi Aoyama,Minesh P. Mehta +38 more
TL;DR: The updated Graded Prognostic Assessment (GPA) provides an accurate tool with which to estimate survival, individualize treatment, and stratify clinical trials and is recommended for expansion of eligibility to allow for the enrollment of patients with previously treated brain metastases.
Journal ArticleDOI
Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA).
Paul W. Sperduto,Wen Jiang,Paul D. Brown,Steve Braunstein,Penny K. Sneed,Daniel A. Wattson,Helen A. Shih,Ananta S Bangdiwala,Ryan Shanley,Natalie A. Lockney,Kathryn Beal,Emil Lou,Thomas Amatruda,William Sperduto,John P. Kirkpatrick,Norman Yeh,Laurie E. Gaspar,Jason K. Molitoris,Laura Masucci,David Roberge,James B. Yu,Veronica Chiang,Minesh P. Mehta +22 more
TL;DR: The updated Melanoma-molGPA, a user-friendly tool to estimate survival, will facilitate clinical decision making regarding whether and which treatment is appropriate and will also be useful for stratification of future clinical trials.
Journal ArticleDOI
The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases
Paul W. Sperduto,T. Jonathan Yang,Kathryn Beal,Hubert Y. Pan,Paul D. Brown,Ananta S Bangdiwala,Ryan Shanley,Norman Yeh,Laurie E. Gaspar,Steve Braunstein,Penny K. Sneed,John M Boyle,John P. Kirkpatrick,Kimberley S. Mak,Helen A. Shih,Alex Engelman,David Roberge,Nils D. Arvold,Brian M. Alexander,Mark M. Awad,Joseph N. Contessa,Veronica Chiang,J.G. Hardie,Daniel J. Ma,Emil Lou,William Sperduto,Minesh P. Mehta +26 more
TL;DR: EGFR and ALK gene alterations are associated with delayed onset of BM and longer MS relative to patients without these alterations, and the CoD was overwhelmingly nonneurologic in patients with known CoD.
Journal ArticleDOI
Beyond an Updated Graded Prognostic Assessment (Breast GPA): A Prognostic Index and Trends in Treatment and Survival in Breast Cancer Brain Metastases From 1985 to Today
Paul W. Sperduto,Shane Mesko,Jing Li,Daniel N. Cagney,Ayal A. Aizer,Nan Lin,Eric Nesbit,Tim J. Kruser,Jason Chan,Steve Braunstein,Jessica W. Lee,John P. Kirkpatrick,William G. Breen,Paul D. Brown,Diana D. Shi,Helen A. Shih,Hany Soliman,Arjun Sahgal,Ryan Shanley,William Sperduto,Emil Lou,Ashlyn S. Everett,Drexell Hunter Boggs,Laura Masucci,David Roberge,Jill Remick,Kristin A. Plichta,John M. Buatti,Supriya K. Jain,Laurie E. Gaspar,Cheng-Chia Wu,Tony J. C. Wang,John Bryant,Michael D. Chuong,James B. Yu,Veronica Chiang,Toshimichi Nakano,Hidefumi Aoyama,Minesh P. Mehta +38 more
TL;DR: MS has improved modestly, but varies widely by diagnosis-specific prognostic factors, and data suggest HER2-targeted therapies improve clinical outcomes in some patients with BCBM.